POLYMER WITH STEPWISE-VARIABLE SURFACE COMPOSITIONS

生物材料科学的进展一直很缓慢，原因是 部分原因是缺乏具有阶梯变表面的模型材料 组成。此外，系统控制的能力 聚合物表面化学在化学领域具有很大的实用价值。 (经验)组织工程用新型生物材料的发展 并用于体外和体内装置和假体。我们的 初步工作表明，虽然利率明显较低， 聚合物共混物的平衡表面张力/组成为 与液体中常规液体表面活性剂的定量相似 溶剂。表面能最小化驱动表面过程 取决于界面性质的平衡，例如， 空气对血。拟议的研究将衡量效率 以及新型表面活性固体聚合物的有效性 表面修饰低聚端基)，在模型碱聚合物中。 需要检验的假设是非晶态或半晶态 关于表面，聚合物是“慢动作的液体” 化学成分与主体成分的对比。一个积极的结果将解释 以下聚合物表面组成随时间的变化 处理或环境的改变。核实 固体/固体聚合物共混物与液体/液体共混物的相似性 混合将为广泛的问题解决提供基础 涉及表面控制的聚合物应用范围 化学反应。第一阶段的结果将在H阶段期间用于 开发商业化的聚合物表面改性工艺 有多种终端用途，包括管材、血液过滤器、血液 氧合器、血液分离/血液储存和其他非医用设备 申请。 建议的商业应用这些聚合物特别是 适用于医疗器械的制造 用于与血液和组织接触。医疗方面的例子 设备包括导管，血管移植物，人工心脏瓣膜， 各种血泵和人造器官。

Advancements in the science of biomaterials have been slow due in part to the lack of model materials with stepwise-variable surface composition. Furthermore, the ability to systematically control polymer surface chemistry would have great practical utility in the (empirical) development of new biomaterials for tissue engineering and for use in ex vivo and in vivo devices and prostheses. Our preliminary work suggests that while rates are significantly lower, equilibrium surface tension/composition of polymer blends is quantitatively similar to conventional liquid surfactants in liquid solvents. Surface energy minimization drives the process of surface equilibration which depends on the nature of the interface, e.g., air versus blood. The proposed study would measure the efficiency and effectiveness of novel surface-active solid polymers (with surface-modifying oligomeric end groups), in a model base polymer. The hypothesis to be tested is that amorphous or semi-crystalline polymers are 'liquids in slow motion' with regard to surface chemistry versus bulk composition. A positive outcome would explain time-dependent changes in polymer surface composition following processing or a change in environment. Verification of the similarities between solid/solid polymer blends and liquid/liquid blends would provide a foundation for problem solving in a wide range of polymer applications involving control of surface chemistry. The results of Phase I will be used during Phase H to develop commercial process for polymer surface modification that have a variety of end uses, including tubing, blood filters, blood oxygenator, blood fractionation/blood storage, and other non-medical applications. PROPOSED COMMERCIAL APPLICATIONS These polymers are particularly suitable for use in the manufacture of medical devices intended to be used in contact with blood and tissue. Examples of medical devices include catheters, vascular grafts, prosthetic heart valves, various blood pumps and artificial organs.